Why carry out this study?

Pulmonary arterial hypertension (PAH) is a debilitating condition marked by its progressive nature with a significant burden on morbidity and mortality.

The phase 3 STELLAR trial has demonstrated the strong clinical benefit of sotatercept as an add-on treatment to stable background therapy for PAH compared to background therapy alone.

To enhance clinicians’ understanding of the potential long-term treatment effectiveness, we developed a population health model based on STELLAR data to predict the long-term morbidity and mortality outcomes of sotatercept plus background therapy vs background therapy alone for patients with PAH.

What was learned from this study?

This study’s findings reveal that adding sotatercept to stable background therapy has the potential to increase life expectancy by roughly threefold among patients with PAH, while reducing utilization of infused prostacyclin, PAH hospitalizations, and lung/heart-lung transplants.